- Home
- GNL vs MNKD Comparison
GNL vs MNKD Comparison
Compare GNL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- MNKD
- Stock Information
- Founded
- GNL 2011
- MNKD 1991
- Country
- GNL United States
- MNKD United States
- Employees
- GNL N/A
- MNKD N/A
- Industry
- GNL Real Estate Investment Trusts
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- GNL Real Estate
- MNKD Health Care
- Exchange
- GNL Nasdaq
- MNKD Nasdaq
- Market Cap
- GNL 1.7B
- MNKD 1.7B
- IPO Year
- GNL N/A
- MNKD 2004
- Fundamental
- Price
- GNL $7.62
- MNKD $5.59
- Analyst Decision
- GNL Buy
- MNKD Strong Buy
- Analyst Count
- GNL 3
- MNKD 5
- Target Price
- GNL $8.67
- MNKD $10.80
- AVG Volume (30 Days)
- GNL 1.3M
- MNKD 4.6M
- Earning Date
- GNL 11-05-2025
- MNKD 11-05-2025
- Dividend Yield
- GNL 9.93%
- MNKD N/A
- EPS Growth
- GNL N/A
- MNKD 149.32
- EPS
- GNL N/A
- MNKD 0.11
- Revenue
- GNL $768,986,000.00
- MNKD $301,736,000.00
- Revenue This Year
- GNL N/A
- MNKD $14.78
- Revenue Next Year
- GNL N/A
- MNKD $19.36
- P/E Ratio
- GNL N/A
- MNKD $51.66
- Revenue Growth
- GNL 24.38
- MNKD 21.48
- 52 Week Low
- GNL $6.51
- MNKD $3.38
- 52 Week High
- GNL $8.35
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- GNL 42.58
- MNKD 56.79
- Support Level
- GNL $7.50
- MNKD $5.24
- Resistance Level
- GNL $7.73
- MNKD $5.72
- Average True Range (ATR)
- GNL 0.17
- MNKD 0.22
- MACD
- GNL -0.01
- MNKD 0.00
- Stochastic Oscillator
- GNL 27.45
- MNKD 81.43
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.